Comparative Pharmacology
Head-to-head clinical analysis: NORINYL 1 50 28 DAY versus TATUM T.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORINYL 1 50 28 DAY versus TATUM T.
NORINYL 1+50 28-DAY vs TATUM-T
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Norethindrone and ethinyl estradiol combination works by suppressing gonadotropin-releasing hormone (GnRH) from the hypothalamus, reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion, thereby inhibiting ovulation. Norethindrone also alters cervical mucus viscosity and endometrial lining, impeding sperm penetration and implantation.
TATUM-T is a combination of ethynodiol diacetate, a progestin, and ethinyl estradiol, an estrogen. It suppresses gonadotropin (FSH and LH) release from the pituitary, inhibiting ovulation. Additionally, it increases viscosity of cervical mucus, impeding sperm penetration, and alters the endometrium to reduce implantation likelihood.
One tablet orally once daily for 28 days, with 7 inactive tablets during the last 7 days. Each active tablet contains norethindrone 1 mg and ethinyl estradiol 50 mcg.
One tablet (ethinyl estradiol 0.035 mg / norgestimate 0.250 mg) orally once daily for 21 days, followed by 7 days of placebo.
None Documented
None Documented
Norethindrone: ~8-11 hours; Mestranol: 24 hours (prodrug, ethinyl estradiol half-life ~13-27 hours).
Terminal elimination half-life of 12-15 hours in healthy adults; prolonged in renal impairment (up to 30 hours in creatinine clearance <30 mL/min) requiring dose adjustment
Renal: ~40% as metabolites; Biliary/Fecal: ~60% as metabolites.
Primarily renal (65-70% as unchanged drug); biliary/fecal (20-25%); minor metabolism to inactive glucuronide conjugates (<10%)
Category C
Category C
Oral Contraceptive
Oral Contraceptive